Cogent Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
12analysts covering
FY Revenue (est.)
$11.9Mnext fiscal year
FY EPS (est.)
-$2.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PDUFA Target Action Date for Bezuclastinib in Combination with Sunitinib for Patients with GIST | 30 Nov 2026 |
| PDUFA Target Action Date for Bezuclastinib in Non-Advanced Systemic Mastocytosis (NonAdvSM) | 30 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Bezuclastinib Clinical Trial Progression (Phase 3 PEAK, Phase 2 SUMMIT, Phase 2 APEX) QuarterlyTarget: Successful completion and regulatory submissions
Cash Runway (Cash, Cash Equivalents, and Marketable Securities) Quarterly866.4MTarget: Sufficient liquidity to fund operations into 2028
Research and Development (R&D) Expenses Quarterly75.4MTarget: Manageable clinical development spend
Watch Items
- FDA Priority Review Decision for Bezuclastinib in Combination with Sunitinib for Patients with GISTTrigger: PDUFA Target Action Date (November 30, 2026)Action: Monitor FDA regulatory decision on or before the PDUFA date of November 30, 2026
- FDA Review of New Drug Application (NDA) for Bezuclastinib in Non-Advanced Systemic Mastocytosis (NonAdvSM)Trigger: PDUFA Target Action Date (December 30, 2026)Action: Monitor FDA regulatory decision on or before the PDUFA target action date of December 30, 2026
- Clinical Trial Data Updates for Early-Stage Pipeline (JAK2 V617F, ErbB2, PI3K̑)Trigger: Presentation of Phase 1 or Preclinical DataAction: Evaluate therapeutic differentiation and safety profiles at upcoming medical congresses
Research as of 19 Jun 2026